Advanced search
Publication Cover
Modern Rheumatology Volume 31, 2021 - Issue 2
Journal homepage
1,182
Views
1
CrossRef citations to date
0
Altmetric
Rheumatoid Arthritis

Radiographic and clinical effects of 10 mg and 25 mg twice-weekly etanercept over 52 weeks in Japanese patients with active rheumatoid arthritis

Tsutomu Takeuchia Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, JapanCorrespondence[email protected]
View further author information
,
Nobuyuki Miyasakab Department of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, Tokyo, JapanView further author information
,
Ron D. Pedersenc Pfizer, Collegeville, PA, USAView further author information
,
Noriko Sugiyamad Clinical Statistics, Biometrics, and Data Management, Pfizer R&D Japan, Tokyo, JapanView further author information
&
Tomohiro Hirosee Immunology & Inflammation Medical Affairs, Innovative Medicines Business, Pfizer Japan Inc, Tokyo, JapanView further author information
Pages 319-325 | Received 03 Jul 2020, Accepted 31 Jul 2020, Published online: 07 Sep 2020

References

  • Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol. 2006;16(2):63–7.
  • Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Japan Biological Agent Study Integrated Consortium, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol. 2010;20(6):531–8.
  • Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21(4):343–51.
  • Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs. J Rheumatol. 2013;40(10):1658–68.
  • Mochizuki T, Momohara S, Yano K, Shirahata T, Ikari K. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly. Mod Rheumatol. 2013;23(5):994–1000.
  • Yamanaka H, Nagaoka S, Lee SK, Bae SC, Kasama T, Kobayashi H, the ENCOURAGE study group, et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity – results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Mod Rheumatol. 2016;26(5):651–61.
  • Yamanaka H, Hirose T, Endo Y, Sugiyama N, Fukuma Y, Morishima Y, et al. Three-year safety and two-year effectiveness of etanercept in patients with rheumatoid arthritis in Japan: Results of long-term postmarketing surveillance. Mod Rheumatol 2019;29(5):737–46.
  • Takeuchi T, Miyasaka N, Zang C, Alvarez D, Fletcher T, Wajdula J, et al. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. Mod Rheumatol. 2013;23(4):623–33.
  • Takeuchi T, Miyasaka N, Kawai S, Sugiyama N, Yuasa H, Yamashita N, et al. Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials. Mod Rheumatol. 2015;25(2):173–86.
  • Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2010;6(11):644–52.
  • Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130(6):478–86.
  • Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586–93.
  • Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46(6):1443–50.
  • Khan MA. HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol. 1995;7(4):263–9.
  • Zhu H, Xia W, Mo XB, Lin X, Qiu YH, Yi NJ, et al. Gene-based genome-wide association analysis in European and Asian populations identified novel genes for rheumatoid arthritis. PLoS One. 2016;11(11):e0167212.
  • Feng J, Chen Q, Yu F, Wang Z, Chen S, Jin Z, et al. Body mass index and risk of rheumatoid arthritis: a meta-analysis of observational studies. Medicine (Baltimore). 2016;95(8):e2859.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.